Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: Past, present, and future perspectives
- Author
- CAMPIANI, Giuseppe1 ; RAMUNNO, Anna2 ; MAGA, Giovanni3 ; NACCI, Vito1 ; FATTORUSSO, Caterina4 ; CATALANOTTI, Bruno2 ; MORELLI, Elena5 ; NOVELLINO, Ettore5
[1] Dipartimento Farmaco Chimico Tecnologico, Universita'degli Studi di Siena, via Aldo Moro, 53100 Siena, Italy
[2] Dipartimento di Scienze Farmaceutiche, Universita'degli Studi di Salerno, via Ponte Don Melillo 11C, 84084 Fisciano (Salerno), Italy
[3] Istituto di Genetica Biochimica ed Evoluzionistica (IGBE) - CNR, via Abbiategrasso 207, 27100 Pavia, Italy
[4] Dipartimento di Chimica delle Sostanze Naturali, Universita'degli Studi di Napoli Federico II, via D., Montesano 49, 80131 Napoli, Italy
[5] Dipartimento di Chimica Farmaceutica e Tossicologica, Universita'degli Studi di Napoli Federico II, via D. Montesano 49, 80131 Napoli, Italy - Issue title
- Anti-HIV design
- Author (monograph)
- PARANG, Keykavous (Editor)1
[1] Department of Biomedical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI 02881, United States - Source
Current pharmaceutical design. 2002, Vol 8, Num 8, pp 615-657 ; ref : 200 ref
- ISSN
- 1381-6128
- Scientific domain
- Pharmacology drugs
- Publisher
- Bentham Science, Hilversum
- Publication country
- Netherlands
- Document type
- Article
- Language
- English
- Keyword (fr)
- Activité biologique Antiviral Article synthèse Association médicamenteuse Chimiothérapie Composé non nucléoside Homme In vitro In vivo Inhibiteur reverse transcriptase Interaction médicamenteuse Mécanisme action Relation structure activité Résistance Structure chimique Traitement Virose Virus HIV1 Infection Lentivirus Retroviridae Virus immunodéficience humaine Virus
- Keyword (en)
- Biological activity Antiviral Review Drug combination Chemotherapy Non nucleoside compound Human In vitro In vivo Reverse transcriptase inhibitor Drug interaction Mechanism of action Structure activity relation Resistance Chemical structure Treatment Viral disease HIV-1 virus Infection Lentivirus Retroviridae Human immunodeficiency virus Virus
- Keyword (es)
- Actividad biológica Antiviral Artículo síntesis Asociación medicamentosa Quimioterapia Compuesto no nucleósido Hombre In vitro In vivo Inhibitor reverse transcriptase Interacción medicamentosa Mecanismo acción Relación estructura actividad Resistencia Estructura química Tratamiento Virosis HIV-1 virus Infección Lentivirus Retroviridae Human immunodeficiency virus Virus
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02S Antibiotics. Antiinfectious agents. Antiparasitic agents / 002B02S05 Antiviral agents
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 13612033
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.2174/1381612024607207 
https://dx.doi.org/10.2174/1381612024607207
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.2174\/1381612024607207\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:98:\"Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: Past, present, and future perspectives\";s:9:\"\u0000*\u0000jtitle\";s:29:\"Current pharmaceutical design\";s:9:\"\u0000*\u0000stitle\";s:16:\"Curr. pharm. des\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:1:\"8\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:3:\"615\";s:8:\"\u0000*\u0000epage\";s:3:\"657\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"CAMPIANI\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Giuseppe\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:13:\"RAMUNNO, Anna\";i:1;s:14:\"MAGA, Giovanni\";i:2;s:11:\"NACCI, Vito\";i:3;s:20:\"FATTORUSSO, Caterina\";i:4;s:18:\"CATALANOTTI, Bruno\";i:5;s:14:\"MORELLI, Elena\";i:6;s:17:\"NOVELLINO, Ettore\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:15:\"Anti-HIV design\";s:8:\"\u0000*\u0000title\";s:98:\"Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: Past, present, and future perspectives\";s:8:\"\u0000*\u0000place\";s:9:\"Hilversum\";s:6:\"\u0000*\u0000pub\";s:15:\"Bentham Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.2174\/1381612024607207\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:98:\"Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: Past, present, and future perspectives\";s:9:\"\u0000*\u0000jtitle\";s:29:\"Current pharmaceutical design\";s:9:\"\u0000*\u0000stitle\";s:16:\"Curr. pharm. des\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:1:\"8\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:3:\"615\";s:8:\"\u0000*\u0000epage\";s:3:\"657\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"CAMPIANI\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Giuseppe\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:13:\"RAMUNNO, Anna\";i:1;s:14:\"MAGA, Giovanni\";i:2;s:11:\"NACCI, Vito\";i:3;s:20:\"FATTORUSSO, Caterina\";i:4;s:18:\"CATALANOTTI, Bruno\";i:5;s:14:\"MORELLI, Elena\";i:6;s:17:\"NOVELLINO, Ettore\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:15:\"Anti-HIV design\";s:8:\"\u0000*\u0000title\";s:98:\"Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: Past, present, and future perspectives\";s:8:\"\u0000*\u0000place\";s:9:\"Hilversum\";s:6:\"\u0000*\u0000pub\";s:15:\"Bentham Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:24:\"10.2174\/1381612024607207\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.2174\/1381612024607207\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:98:\"Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: Past, present, and future perspectives\";s:9:\"\u0000*\u0000jtitle\";s:29:\"Current pharmaceutical design\";s:9:\"\u0000*\u0000stitle\";s:16:\"Curr. pharm. des\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:1:\"8\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:3:\"615\";s:8:\"\u0000*\u0000epage\";s:3:\"657\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"CAMPIANI\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Giuseppe\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:13:\"RAMUNNO, Anna\";i:1;s:14:\"MAGA, Giovanni\";i:2;s:11:\"NACCI, Vito\";i:3;s:20:\"FATTORUSSO, Caterina\";i:4;s:18:\"CATALANOTTI, Bruno\";i:5;s:14:\"MORELLI, Elena\";i:6;s:17:\"NOVELLINO, Ettore\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:15:\"Anti-HIV design\";s:8:\"\u0000*\u0000title\";s:98:\"Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: Past, present, and future perspectives\";s:8:\"\u0000*\u0000place\";s:9:\"Hilversum\";s:6:\"\u0000*\u0000pub\";s:15:\"Bentham Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.2174\/1381612024607207\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:98:\"Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: Past, present, and future perspectives\";s:9:\"\u0000*\u0000jtitle\";s:29:\"Current pharmaceutical design\";s:9:\"\u0000*\u0000stitle\";s:16:\"Curr. pharm. des\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:1:\"8\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:3:\"615\";s:8:\"\u0000*\u0000epage\";s:3:\"657\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"CAMPIANI\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Giuseppe\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:13:\"RAMUNNO, Anna\";i:1;s:14:\"MAGA, Giovanni\";i:2;s:11:\"NACCI, Vito\";i:3;s:20:\"FATTORUSSO, Caterina\";i:4;s:18:\"CATALANOTTI, Bruno\";i:5;s:14:\"MORELLI, Elena\";i:6;s:17:\"NOVELLINO, Ettore\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:15:\"Anti-HIV design\";s:8:\"\u0000*\u0000title\";s:98:\"Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: Past, present, and future perspectives\";s:8:\"\u0000*\u0000place\";s:9:\"Hilversum\";s:6:\"\u0000*\u0000pub\";s:15:\"Bentham Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.2174\/1381612024607207\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:98:\"Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: Past, present, and future perspectives\";s:9:\"\u0000*\u0000jtitle\";s:29:\"Current pharmaceutical design\";s:9:\"\u0000*\u0000stitle\";s:16:\"Curr. pharm. des\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:1:\"8\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:3:\"615\";s:8:\"\u0000*\u0000epage\";s:3:\"657\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"CAMPIANI\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Giuseppe\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:13:\"RAMUNNO, Anna\";i:1;s:14:\"MAGA, Giovanni\";i:2;s:11:\"NACCI, Vito\";i:3;s:20:\"FATTORUSSO, Caterina\";i:4;s:18:\"CATALANOTTI, Bruno\";i:5;s:14:\"MORELLI, Elena\";i:6;s:17:\"NOVELLINO, Ettore\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:15:\"Anti-HIV design\";s:8:\"\u0000*\u0000title\";s:98:\"Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: Past, present, and future perspectives\";s:8:\"\u0000*\u0000place\";s:9:\"Hilversum\";s:6:\"\u0000*\u0000pub\";s:15:\"Bentham Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
